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Background:  The cost burden of heart failure (HF) to society and the healthcare system is substantial. Identifying variability across patient 
subgroups may assist in enhancing disease management. This study examined HF-related therapy among patients with HF, and the 
relationship with healthcare costs and healthcare resource utilization (HCRU).
methods:  A retrospective study of medical and pharmacy claims data from a large US health plan (commercial and Medicare Advantage 
enrollees) was conducted. Included individuals were ≥18 years with 2 medical or 1 inpatient claim(s) with ICD-9-CM diagnosis code for 
HF (402.x1, 404.x1, 404.x3, 428.xx). Date of earliest claim for HF during 01Jan2010-31Dec2011was defined as the index date. Cohort 
assignment (2) was based on pharmacy claims for HF-related therapy (angiotensin-converting enzyme inhibitor, angiotensin-receptor 
blocker, beta blocker, aldosterone receptor antagonist, diuretic, digoxin, hydralazine plus isosorbide dinitrate) within 60 days post-index. 
Per-subject-per-month (PSPM) and yearly healthcare costs (all-cause) and HCRU (all-cause and HF-related) were calculated for up to 24 
months following index date. Independent samples t-tests and Pearson’s chi-square tests were used to examine differences in post-index 
healthcare costs and HCRU, respectively, by cohort.
results:  A total of 118,385 individuals with claims for HF (median age 74 years, 52% female, 75% Medicare Advantage) were identified; 
28% without claims for HF related-therapy within 60 days post-index. Compared to those with HF related-therapy, subjects without HF 
related-therapy experienced higher total medical (PSPM: $9,358 vs $4,161; year 1: $40,578 vs $35,742; p<.001; year 2 similar) and 
inpatient all-cause costs (PSPM: $7,301 vs $2,623; year 1: $27,086 vs $21,765; p<.001; year 2 similar). Additionally, a larger percentage of 
subjects without HF related-therapy were hospitalized (all-cause: 74% vs 71%; HF-related: 65% vs 62%; p<.001) compared to those with 
HF related-therapy.
conclusion:  Over a quarter of patients with HF remain untreated 60 days following an index HF-related encounter; these findings suggest 
more aggressive management of HF is needed.
